Management Team

BioNTech’s international Management team is highly experienced with backgrounds spanning academia, big pharma, entrepreneurial and innovative emerging biopharma and many geographies including USA, UK and Europe.

Management Board

Prof. Dr. Ugur Sahin

Prof. Dr. Ugur Sahin

Co-Founder & CEO

Prof. Ugur Sahin, M.D. is an entrepreneurial researcher and inventor who has made essential contributions to more than 60 independent patents in various life science and biotechnology fields, including pioneering innovations that provide the basis for the foundation of BioNTech AG.

Sean Marett

Sean Marett

CBO & CCO

Sean Marett has 30 years of international experience in the management of operations, sales and marketing licensing, M&A and new product development.

Dr. Sierk Poetting

Dr. Sierk Poetting

CFO & COO

Sierk Poetting, Ph.D. has worked for large pharma companies covering a broad range of responsibilities, such as integrating several acquired companies, supporting the execution of numerous M&A and licensing deals.

Dr. Özlem Türeci

Dr. Özlem Türeci

CMO

Özlem Türeci is an M.D. with over 25 years of experience in cancer research and immuno-oncology, specifically in the identification of immunotherapeutic drug targets and the development of antibodies, as well as vaccine-based therapies.

Vice Presidents

Prof. Dr. Katalin Karikó

Prof. Dr. Katalin Karikó

Vice President RNA Protein Replacement Therapy BioNTech RNA Pharmaceuticals GmbH

Prof. Katalin Karikó, Ph.D. leads the mRNA-based protein replacement program for BioNTech RNA Pharmaceuticals GmbH. She has more than 30 years of experience working with RNA.

Dr. Andreas Kuhn

Dr. Andreas Kuhn

Vice President RNA Biochemistry BioNTech RNA Pharmaceuticals GmbH

Andreas Kuhn, Ph.D. has worked in the field of RNA biochemistry and molecular biology for more than twenty years.

Dr. Heinrich Haas

Dr. Heinrich Haas

Vice President Drug Delivery BioNTech RNA Pharmaceuticals GmbH

Heinrich Haas, Ph.D. has more than 18 years of experience in academic research and industrial pharmaceutical development. After he received his Ph.D. in physical chemistry, Dr. Haas researched lipid membranes and organized biomolecular systems.

Dr. Michael Oed

Dr. Michael Oed

Vice President Product Development BioNTech Diagnostics GmbH

Michael Oed, Ph.D. has more than 25 years of professional experience in design, development, manufacturing, clinical validation and national/international regulatory approval of in vitro diagnostic devices (IVDs).

Dr. Sylke Maas

Dr. Sylke Maas

Vice President Investor Relations & Business Strategy BioNTech

Sylke Maas, Ph.D. is responsible for Investor Relations and Business Strategy at BioNTech AG. Before taking over this role she has been responsibility for Global Marketing and Sales at BioNTech AG for more than 4 years.

Dr. Oliver Hennig

Dr. Oliver Hennig

Vice President Operations BioNTech

Oliver Hennig, Ph.D. is an experienced project and product lifecycle manager who has been implementing these methodologies, using various business models, for products and solutions on a global scale.

Dr. Felicitas Müller

Dr. Felicitas Müller

Vice President Scientific Alliances BioNTech

Felicitas Müller, Ph.D. is responsible for content related coordination of the scientific cooperations at BioNTech. She holds a doctorate in clinical biochemistry and pathobiochemistry and spent several years as an academic researcher at the Karolinska Institute in Sweden.

Dr. Zuzana Trnkova, M.D

Dr. Zuzana Trnkova, M.D

Vice President Clinical Research BioNTech

Zuzana Jirakova Trnkova, M.D., Ph.D. has over 15 years of academy and international pharmaceutical industry experience in cancer drug development including several successful global submissions of oncology compounds. She holds a doctorate in immunology and molecular biology.

Jim Baker, MBA

Jim Baker, MBA

Vice President Global Marketing & Commercial Development BioNTech

Jim Baker is responsible for Global Marketing and Commercial Development at BioNTech AG. He has more than 25 years clinical and commercial experience within the healthcare industry, primarily within the field of oncology.

Rita Kelley-Reiter

Rita Kelley-Reiter

Vice President Global Marketing & Commercial Development BioNTech

Rita Kelley-Reiter is responsible for Global Marketing and Commercial Development at BioNTech AG. She has more than 25 years of global and regional clinical, and commercial experience within the healthcare industry, specializing in field of hematology and oncology.

James Ryan, Ph.D.

James Ryan, Ph.D.

Vice President Legal & Intellectual Property BioNTech

James Ryan, Ph.D. brings more than 15 years of experience providing counsel to the biopharmaceutical industry on legal, IP and corporate governance issues, both in private practice and in senior in-house roles.

Scientific Advisory Board

Prof. Dr. Rolf Zinkernagel

Prof. Dr. Rolf Zinkernagel is Professor Emeritus at the University of Zurich, University Hospital, Zurich and former head of the Institute of Experimental Immunology, Zurich.

Prof. Dr. Hans Hengartner

Prof. Dr. Hans Hengartner is Professor Emeritus at the Federal Institute of Technology ETH Zurich and University of Zurich.

Executive Advisors

Dr. Sebastian Kreiter

Dr. Sebastian Kreiter

Sebastian Kreiter, M.D. developed the fundamentals of the Ribological® RNA vaccine platform under the guidance of Ugur Sahin. They have been working together since 2001.

Dr. Mustafa Diken

Dr. Mustafa Diken

Mustafa Diken, Ph.D. received his Ph.D. in tumor immunology from Johannes Gutenberg University, Mainz and is currently the Deputy Director of the Immunotherapy Development Center at TRON GmbH.